Restore Medical has developed the ContraBand™ system, a transcatheter Pulmonary Artery Banding device designed to provide support to the left ventricle in patients with heart failure with reduced ejection fraction (HFrEF). This reversible therapy improves left ventricular ejection fraction and restores optimal ventricular geometry, addressing the lack of approved treatments for this condition.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with heart failure with reduced ejection fraction (HFrEF) have limited treatment options to improve left ventricular function. Current therapies often fail to restore optimal ventricular geometry, leading to continued morbidity and mortality.
Solution
Restore Medical's ContraBand™ system is a transcatheter Pulmonary Artery Banding (PAB) device designed to provide support to the left ventricle in HFrEF patients. Delivered via catheter, this implant leverages the right ventricle to support the left ventricle, improving ejection fraction and restoring optimal ventricular geometry. The ContraBand™ system offers a reversible therapy to address the unmet need for effective treatments for this condition.
Target Audience
The primary target audience includes interventional cardiologists and heart failure specialists treating patients with heart failure with reduced ejection fraction (HFrEF).
Features
- Transcatheter delivery system for minimally invasive implantation
- Pulmonary Artery Banding (PAB) mechanism to support the left ventricle
- Reversible design allowing for adjustments or removal if necessary
- Designed to improve left ventricular ejection fraction (LVEF)
- Aims to restore favorable left ventricular geometry